Deals channel feed

With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

5 years ago
R&D

Al­ta­sciences, true to its word, ex­pands its foot­print with ac­qui­si­tion of Penn­syl­va­nia CRO

5 years ago
Manufacturing

Bounc­ing back from a shock­ing CRL, Athenex shares soar with buy­out of nat­ur­al killer T cell play­er

5 years ago

A biotech with a yen for pricey rare dis­ease drugs — and bar­gain base­ment shop­ping — adopts an­oth­er or­phan in lat­est M&A pact

5 years ago

Sig­ma-Aldrich hit with $9M fine for mis­lead­ing in­fo dur­ing Mer­ck KGaA merg­er

5 years ago
FDA+

Astel­las walks away from $450M+ Cy­to­ki­net­ics pact af­ter tak­ing a few ex­tra months to see progress

5 years ago

A mus­cled up Mod­er­na fi­nal­ly joins the CO­V­AX crew, pledg­ing 500M dos­es for low-in­come coun­tries

5 years ago
Coronavirus

Am­plyx laid out a promis­ing path to a piv­otal an­ti­fun­gal drug tri­al, and now Pfiz­er is scoop­ing it all up in a buy­out

5 years ago

Es­pe­ri­on's strug­gling-to-mar­ket, would-be block­buster finds fresh in­fu­sion of cash

5 years ago

The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

5 years ago

As Mod­er­na rose, Flag­ship cashed in for $1.4B — with a lot more wealth still re­main­ing

5 years ago

Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem

5 years ago

Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird -- and re­new­ing an­a­lyst­s' skep­ti­cism

5 years ago

Kazia swipes an ex-Sanofi mol­e­cule for £1M up­front as they look to repli­cate their Genen­tech snag

5 years ago

Q1: A flood of in­vestor cash drove biotech's num­bers to new record highs, and the tor­rent of cash is mov­ing up­stream fast

5 years ago

As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

5 years ago
Pharma

In one of their first ever ac­qui­si­tions, Re­lay bets $85M cash on a new AI-based screen­ing ap­proach

5 years ago

An­oth­er big CRO deal has land­ed as Ther­mo Fish­er ac­quires PPD for $17.4B

5 years ago

An­ti-ag­ing biotech up­start plucks a drug from Am­gen's dis­card pile, piv­ot­ing from heart fail­ure to mus­cle con­di­tions

5 years ago

Eli Lil­ly seeds a well-con­nect­ed Chi­na neu­ro start­up with drugs aim­ing at where Bio­gen, Voy­ager missed

5 years ago
China

Af­ter be­ing goad­ed to sell the com­pa­ny, Alex­ion's CEO set some am­bi­tious new goals for in­vestors. Then Pas­cal So­ri­ot came call­ing

5 years ago

Tim Lu’s gene-cir­cuit star Sen­ti signs up for a $645M dis­cov­ery al­liance with Roche sub Spark

5 years ago

Neil Ku­mar's Bridge­Bio finds 7 new aca­d­e­m­ic part­ners to join the fight against ge­net­ic dis­ease

5 years ago

End­points ex­clu­sive: Bob Nelsen's Re­silience snags Flori­da CD­MO work­ing with the De­fense De­part­ment on Covid-19 an­ti­body

5 years ago
First page Previous page 77787980818283 Next page Last page
A service from the Financial Times